Included here is a list of publications from OCG programs. All published data are available to the research community through the program-specific data matrices.
* denotes publications from the CTD2 initiative that are results of intra-Network collaborations
The findings presented in this manuscript establish CTCF as a prominent tumor-suppressor gene and point to CTCF-mediated epigenetic stability as a major barrier to neoplastic progression.
Researchers elucidate endogenous barriers limiting the process of reprogramming somatic cells to induced pluripotent stem cells by systematically dissecting human cellular reprogramming.
Researchers discuss the development of effective targeted therapy to manage Group 3 medulloblastomas by targeting α5-GABA-A receptor.
The transcriptional coactivator YAP1 rescued cell viability in KRAS-dependent cells upon suppression of KRAS and was required for KRAS-induced cell transformation.
Investigators find that acute myeloid leukemias with MLL fusions are dependent on CDK6, offering a therapeutic strategy.
BET proteins are critical regulators of the Hedgehog pathway, suggesting that BET inhibitors may be used to treat Hedgehog-driven tumors.
Authors develop a computational approach for automated quantitation of off-target effects in RNAi screening data sets.
Researchers present methods which are specifically designed to handle cancer-related copy-number profiles.
In an effort to identify biomarkers of recurrence for Prostate cancer, researchers performed global RNA sequencing on 106 formalin-fixed, paraffin-embedded prostatectomy samples from 100 patients at three independent sites, defining a 24-gene signature panel.
Researchers use reverse-phase protein arrays to study the proteome and compare it to the genomic and transcriptome analysis of 11 TCGA pan-cancer diseases.